Asher Chanan-Khan - 07 Jul 2026 Form 4 Insider Report for Cellectar Biosciences, Inc. (CLRB)

Reporting relationship
Director
Issuer ticker
CLRB
Reported as of
07 Jul 2026
Net transaction value
$0
Source evidence Original filing metadata and source links for verification. 4 source fields
SEC form
4
Accepted by SEC
08 Jul 2026, 21:09:03 UTC
Prior SEC filing
18 Feb 2025
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Asher Chanan-Khan

Key filing fact

Asher Chanan-Khan filed Form 4 for Cellectar Biosciences, Inc. (CLRB) on 08 Jul 2026.

Key facts

  • This page summarizes Asher Chanan-Khan's Form 4 filing for Cellectar Biosciences, Inc. (CLRB).
  • 1 reported transaction and 1 derivative row are listed below.
  • Accepted by SEC: 08 Jul 2026, 21:09.

Change

  • Previous filing in this sequence was filed on 18 Feb 2025.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001869837 Primary reporting owner

Chanan-Khan Asher

Relationship
Director
Address
C/O CELLECTAR BIOSCIENCES, INC., 100 CAMPUS DRIVE, FLORHAM PARK
Signature
/s/ Asher Chanan-Khan
Signature date
08 Jul 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CLRB transaction Derivative

Stock option (right to buy)

Award

Transaction value
Shares
+25,000
Change %
Price
$0.000000*
Shares after
25,000
Date
07 Jul 2026
Ownership
Direct
Underlying class
Common stock
Underlying amount
25,000
Exercise price
$2.70
Footnotes
F1
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

This option shall vest in full on July 7, 2027, subject to the reporting person's continued service through the applicable vesting date.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .